key: cord-0903098-22x7wipd
authors: Cao, Yunlong; Wang, Jing; Jian, Fanchong; Xiao, Tianhe; Song, Weiliang; Yisimayi, Ayijiang; Huang, Weijin; Li, Qianqian; Wang, Peng; An, Ran; Wang, Yao; Niu, Xiao; Yang, Sijie; Liang, Hui; Sun, Haiyan; Li, Tao; Yu, Yuanling; Cui, Qianqian; Liu, Shuo; Yang, Xiaodong; Du, Shuo; Zhang, Zhiying; Hao, Xiaohua; Shao, Fei; Jin, Ronghua; Wang, Xiangxi; Xiao, Junyu; Wang, Youchun; Xie, Xiaoliang Sunney
title: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
date: 2021-12-22
journal: bioRxiv
DOI: 10.1101/2021.12.07.470392
sha: 20f6291083a88361c07540b57ced3e45d0ac9b12
doc_id: 903098
cord_uid: 22x7wipd

The SARS-CoV-2 B.1.1.529 variant (Omicron) contains 15 mutations on the receptor-binding domain (RBD). How Omicron would evade RBD neutralizing antibodies (NAbs) requires immediate investigation. Here, we used high-throughput yeast display screening1,2 to determine the RBD escaping mutation profiles for 247 human anti-RBD NAbs and showed that the NAbs could be unsupervised clustered into six epitope groups (A-F), which is highly concordant with knowledge-based structural classifications3-5. Strikingly, various single mutations of Omicron could impair NAbs of different epitope groups. Specifically, NAbs in Group A-D, whose epitope overlap with ACE2-binding motif, are largely escaped by K417N, G446S, E484A, and Q493R. Group E (S309 site)6 and F (CR3022 site)7 NAbs, which often exhibit broad sarbecovirus neutralizing activity, are less affected by Omicron, but still, a subset of NAbs are escaped by G339D, N440K, and S371L. Furthermore, Omicron pseudovirus neutralization showed that single mutation tolerating NAbs could also be escaped due to multiple synergetic mutations on their epitopes. In total, over 85% of the tested NAbs are escaped by Omicron. Regarding NAb drugs, the neutralization potency of LY-CoV016/LY-CoV555, REGN10933/REGN10987, AZD1061/AZD8895, and BRII-196 were greatly reduced by Omicron, while VIR-7831 and DXP-604 still function at reduced efficacy. Together, data suggest Omicron would cause significant humoral immune evasion, while NAbs targeting the sarbecovirus conserved region remain most effective. Our results offer instructions for developing NAb drugs and vaccines against Omicron and future variants.

studying NAb's response to Omicron only in the single mutation context is insufficient. 125 Indeed, Omicron pseudovirus neutralization and spike enzyme-linked immunosorbent 126 assay (ELISA) showed that single mutation tolerating NAbs could also be escaped by 127 Omicron due to multiple synergetic mutations on their epitopes ( The VH1-58 gene-encoded NAbs are enriched in Group B (Extended Data Fig. 4b ).

152 These NAbs such as AZD8895 36 , REGN-10933 42 , and BD-836 45 bind to the left 153 shoulder of RBD, often focusing on the far tip (Fig. 2h) . These NAbs are very sensitive 154 to the change of F486, N487, and G476 (Fig 2b, Extended Data Fig. 6b ). Fortunately,

F486 and a few other major targeting sites of these NAbs are critically involved in 156 ACE2-binding, and therefore they are generally harder to be escaped. A subset of NAbs Omicron significantly reduced Group B NAbs' binding affinity to RBD, potentially 159 through S477N/T478K/E484A on their epitope (Extended Data Fig. 7b ) 46 , resulting in 160 the loss of neutralization.

Group C NAbs are frequently encoded by VH1-2 and VH1-69 (Extended Data Fig. 4c) . 163 The majority of NAbs in this group could bind to both "up" and "down" RBDs, 164 resulting in higher neutralization potency compared to other groups (Fig. 2c, Extended 165 Data Fig. 5c ). Several highly potent antibodies are found in Group C, including BD-166 368-2/DXP-593 44 , C002 3 , and LY-CoV555 47 . They bind to the right shoulder of RBD 167 (Fig. 2i) , and are mostly prone to the change of E484 (Extended Data Fig. 6c, 7c) , such 168 as the E484K mutation found in Beta (Fig. 2f) . The E484A mutation seen in Omicron 169 elicited a similar escaping effect, although the change to Ala is slightly subtler, and the mutation rate and CDR3 length are larger than other groups. NAbs in Group E and 190 F rarely compete with ACE2; thus, their average half-maximal inhibitory concentration 191 (IC50) is higher than NAbs in Group A-D (Extended Data Fig. 5c ). NAbs in Group E, such as VIR-7831/S309, may recognize a mixed protein/carbohydrate epitope, 193 involving the N-linked glycan on N343 6 (Fig. 3h) . Inferred from the escaping mutation 194 profiles (Fig. 3b) , Group E NAbs are often sensitive to changes of G339, T345, and 195 R346 (Extended Data Fig 6e, 7e) . The G339D mutation would affect a subset of NAbs' 196 neutralization performance (Fig. 3e) . Also, part of Group E NAbs' epitope would 197 extend to the 440-449 loop, making them sensitive to N440K in Omicron (Fig. 3e ).

Noticeably, the population of Omicron with R346K is continuously increasing, which 199 may severely affect the neutralization capacity of Group E NAbs. Group F NAbs such as S304 target a cryptic site in RBD that is generally not exposed 202 ( Fig. 3i) , therefore their neutralizing activities are generally weaker 7 . Group F NAbs 203 are often sensitive to changes of F374, T376, and K378 (Extended Data Fig. 6f to the epitopes of S2X259 (Fig. 3f, j) , suggesting that they can compete with ACE2.

Indeed, several NAbs, such as BD55-5300 and BD55-3372, exhibit higher 210 neutralization potency than other NAbs in Group F (Fig. 3c, 4b) . However, These 211 antibodies' neutralization capability might be undermined by N501Y and Y505H of 212 Omicron (Fig. 3j) .

As for NAb drugs, consistent with their escaping mutation profiles, the neutralization 215 potency of LY-CoV016/LY-CoV555, REGN-10933/REGN-10987, and AZD1061 are 216 greatly reduced by Omicron (Fig. 4a, Extended Data Fig. 9 ). The binding affinity of 217 AZD8895 and BRII-196 toward Omicron RBD is also significantly reduced, likely due 218 to multiple mutations accumulating on their epitopes, such that AZD8895 and BRII-219 196 failed to neutralize Omicron (Extended Data Fig. 10 ). BRII-198 was not tested 220 since the antibody sequence was not released. VIR-7831 retains strong RBD binding 221 capability, although G339 is part of its epitope, the G339D mutation in Omicron does 222 not appear to affect VIR-7831's binding; however, VIR-7831's IC50 is reduced to 181 223 ng/mL, and may be subject to further reduction against Omicron with R346K. DXP-224 604's binding affinity against Omicron RBD is largely reduced compared to wildtype 225 RBD; nevertheless, it can still neutralize Omicron at an IC50 of 287 ng/mL, a nearly 30-fold reduction compared to wildtype (Fig. 4a) . Additionally, several NAbs in Group 227 E and F have shown high potency against Omicron and broad pan-sarbecovirus 228 neutralization ability, promising for NAb drug development (Fig. 4b) . Many more 229 NAbs identified from vaccinated SARS-CoV-1 convalescents are waiting to be 230 characterized.

The high-throughput yeast screening method provides a laboratory means for quickly 233 examining the epitope of a certain NAb; however, the current throughput using FACS 234 is limited and can not be used to evaluate a large NAb library. By virtue of MACS, we 235 are able to increase the throughput by two orders of magnitude. In doing so, we were To date, a large number of SARS-CoV-2 anti-RBD NAbs have been identified from 244 convalescents and vaccinees. The most potent NAbs are frequently found in Groups A-245 D as we described above, which tend to directly interfere with the binding of ACE2.

Nevertheless, the neutralizing powers of these NAbs are often abrogated by RBD 247 mutations in the evolutionary arms race between SARS-CoV-2 and human humoral 248 immunity. Indeed, we showed that Omicron would escape the majority of SARS-CoV-249 2 NAbs in this collection (Extended Data Fig. 5e The raw FASTQ files were processed by Cell Ranger (version 6.1.1) pipeline using 502 GRCh38 reference. Sequences were generated using "cellranger multi" or "cellranger Processed data of this study has been added to this repository as well. from three biological replicates and represented as mean±s.d. 

Ehling_mAb−64 DH1154 DH1140 C102

Ehling_mAb−50 COV2−2268

BD55−387 BD−